Dr. William Williams reports

BRIACELL THERAPEUTICS CORP. ANNOUNCES RESULTS OF SHAREHOLDER MEETING

Briacell Therapeutics Corp. has released the results of its annual general meeting of shareholders of the company for the year ended July 31, 2023, held on Jan. 30, 2024. A total of 5,375,071 common shares of the company were voted, representing 33.63 per cent of the company's issued and outstanding common shares.

At the meeting, the shareholders overwhelmingly voted in favour of all proposed resolutions, consisting of the reappointment of MNP LLP as auditor of the company for the ensuing year and authorizing the directors to fix its remuneration, and the election of each of Dr. William V. Williams, Jamieson Bondarenko, Marc Lustig, Dr. Jane A. Gross, Dr. Rebecca Taub, Vaughn C. Embro-Pantalony and Martin E. Schmieg as directors of the company.

A total of 5,375,071 common shares were voted in connection with the election of the directors.

The formal report on voting results with respect to all matters voted upon during the meeting will be filed on the company's SEDAR+ profile.

About Briacell Therapeutics Corp.

Briacell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.

We seek Safe Harbor.